Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment
Recent industry sentiment, as revealed on Post-Hoc Live's May 2025 episode, remains cautious to negative, with many executives reporting persistently bad numbers for biotech performance over several years2.
There are approximately 180 public biotech companies trading below their cash value, which is an indicator of poor investor confidence and financial instability within the sector2.
Earlier in 2025, some optimism emerged due to major events like a $10+ billion buyout (Intracellular), suggesting possible recovery and M&A activity. However, this positive momentum was quickly reversed, leaving many experts pessimistic2.
The survey highlighted operational impacts, such as FDA staff turnover and delays:
about 10% of respondents reported regulatory delays, and 17% had seen familiar FDA staffers leave, though these metrics alone do not fully define the industry's outlook2.
Market enthusiasm seen at events like JP Morgan in early 2025 was noted, but subsequent developments suggest that broad-based recovery in biotech remains elusive2.
Overall, the Post-Hoc Live discussion concluded the good times in biotech are not yet back, and ongoing challenges persist, despite isolated signs of hope2.